	US 12,350,256 B2
	Histidine and/or histidine derivative for the treatment of inflammatory skin diseases
Neil Kerslake Gibbs, Cheshire (GB)
Assigned to CURAPEL (SCOTLAND) LIMITED, Glasgow (GB)
Filed by Curapel (Scotland) Limited, Glasgow (GB)
Filed on Dec. 8, 2021, as Appl. No. 17/545,331.
Application 14/950,559 is a division of application No. 12/918,701, abandoned, previously published as PCT/GB2009/000430, filed on Feb. 18, 2009.
Application 17/545,331 is a continuation of application No. 14/950,559, filed on Nov. 24, 2015, abandoned.
Claims priority of application No. 0803054 (GB), filed on Feb. 20, 2008.
Prior Publication US 2022/0096439 A1, Mar. 31, 2022
Int. Cl. A61K 31/4172 (2006.01); A61P 17/00 (2006.01); A61P 17/04 (2006.01); A61P 17/06 (2006.01)

CPC A61K 31/4172 (2013.01) [A61P 17/00 (2018.01); A61P 17/04 (2018.01); A61P 17/06 (2018.01)]

20 Claims

1. A method of treating atopic dermatitis, the method comprising:

administering orally to a human adult subject suffering from atopic dermatitis as a single daily dose a composition comprising 4 g of L-histidine and/or a pharmaceutically acceptable salt thereof in a liquid in the form of a suspension,

the atopic dermatitis being treated.